Latest Breaking News On - Craig stoltz - Page 1 : vimarsana.com

TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission

/PRNewswire/ Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001).

United statesCraig stoltzExchange commissionJanssen biotech incNone of janssen research developmentJanssen research developmentInflammatory bowel disease questionnaireInnovative medicineJanssen researchJanssen biotechPrivate securities litigation reform actAnnual reportNote regarding forward lookingQuarterly reports

Johnson & Johnson submits supplemental Biologics License Application to U S FDA seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis

/PRNewswire/ Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug.

Spring houseBritish columbiaDavid leeScandj rheumatolPrnewswire johnsonCraig stoltzExchange commissionDevices agencyDrug administrationCanadian agency for drugs technologies in healthEuropean commissionNone of janssen research developmentJapan pharmaceuticalsNational institutes of healthJanssen biotech incCrohn colitis foundation

Johnson & Johnson submits supplemental Biologics License Application to U S FDA seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis

Johnson & Johnson submits supplemental Biologics License Application to U S FDA seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Spring houseBritish columbiaCraig stoltzScandj rheumatolPrnewswire johnsonDavid leeEuropean commissionJanssen biotech incDrug administrationNone of janssen research developmentExchange commissionCanadian agency for drugs technologies in healthJapan pharmaceuticalsCrohn colitis foundationJanssen research developmentNational institutes of health

New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year

/PRNewswire/ Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating.

United statesPrnewswire johnsonLaura ferrisLloyd millerCraig stoltzProtagonist therapeutics incUniversity of pittsburghExchange commissionJanssen biotech incAmerican academy of dermatologyNone of janssen research developmentNational psoriasis foundationJanssen research developmentEveryday healthAmerican academyPsoriasis area

New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year

Johnson & Johnson today announced the first data from FRONTIER 2, the long-term extension of the Phase 2b FRONTIER 1 clinical trial evaluating JNJ-2113, the first and only.

United statesCraig stoltzPrnewswire johnsonLloyd millerLaura ferrisJanssen research developmentJanssen biotech incEveryday healthAmerican academy of dermatologyUniversity of pittsburghExchange commissionNational psoriasis foundationNone of janssen research developmentProtagonist therapeutics incAmerican academyPsoriasis area